BSAC先锋系列:不平等与抗生素耐药
COVID-19 has highlighted the worldwide inequities in access to the tools needed to tackle the pandemic. The same is the case for antibiotic resistance (ABR), which is projected to cause far greater devastation.…
要点
- 除非解决中低收入国家的感染性疾病负担,否则无法在全球层面影响抗生素耐药。
- 大量资金投入新抗生素研发和监测系统,却大多忽视了感染预防等干预措施。
- 需要通过大规模公共卫生干预和筹资机制支持中低收入国家做出改变,并在最高层面采取行动。
核心结论
- 除非解决中低收入国家的感染性疾病负担,否则无法在全球层面影响抗生素耐药。
- 尽管付出巨大努力,我们在抗生素节约方面基本失败。
- 需要在最高层面采取行动,并找到筹资机制支持中低收入国家做出改变。
研究设计与样本
- 本文为BSAC先锋系列评论文章,非原始研究,未报告系统检索方法或样本量。
主要发现
- COVID-19凸显了全球在获取应对大流行所需工具方面的不平等,抗生素耐药同样如此且预计将造成更大破坏。
- 已投入数百万美元用于开发新抗生素和监测系统,却大多忽视了感染预防等干预措施。
- 用于环境卫生和清洁用水、疫苗接种以及改变农业实践以减少抗菌药物依赖等干预措施的资源不足。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 has highlighted the worldwide inequities in access to the tools needed to tackle the pandemic. The same is the case for antibiotic resistance (ABR), which is projected to cause far greater devastation. The truth is that unless we tackle the burden of infectious diseases in low- and middle-income countries (LMICs), we will not impact ABR worldwide. Despite valiant efforts we have largely failed to address antibiotic conservation. We have directed millions of dollars into developing new antibiotics and surveillance systems and mostly ignored interventions such as infection prevention. Insufficient resources are dedicated to interventions such as sanitation and clean water, vaccination and changes in agricultural practice to reduce reliance on antimicrobials. Large-scale public health interventions are required. Funding mechanisms must be found to support LMICs in making these changes. Action is required at the highest levels.
引用
- Mendelson M. BSAC Vanguard Series: Inequality and antibiotic resistance. J Antimicrob Chemother. 2022. PMID: 35107142. doi:10.1093/jac/dkab426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。